BRPI0922912A2 - peptídeos de 4-amino-4-oxobutanoil como inibidores de replicação viral - Google Patents

peptídeos de 4-amino-4-oxobutanoil como inibidores de replicação viral

Info

Publication number
BRPI0922912A2
BRPI0922912A2 BRPI0922912A BRPI0922912A BRPI0922912A2 BR PI0922912 A2 BRPI0922912 A2 BR PI0922912A2 BR PI0922912 A BRPI0922912 A BR PI0922912A BR PI0922912 A BRPI0922912 A BR PI0922912A BR PI0922912 A2 BRPI0922912 A2 BR PI0922912A2
Authority
BR
Brazil
Prior art keywords
amino
viral replication
replication inhibitors
oxobutanoyl peptides
oxobutanoyl
Prior art date
Application number
BRPI0922912A
Other languages
English (en)
Inventor
Akihiro Hashimoto
Atul Agarwal
Avinash Phadke
Dawei Chen
Godwin Pais
Ha Young Kim
Milind Deshpande
Shouming Li
Venkat Gadhachanda
Xiangzhu Wang
Original Assignee
Achillion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achillion Pharmaceuticals Inc filed Critical Achillion Pharmaceuticals Inc
Publication of BRPI0922912A2 publication Critical patent/BRPI0922912A2/pt
Publication of BRPI0922912A8 publication Critical patent/BRPI0922912A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
BRPI0922912A 2008-12-10 2009-12-10 peptídeos de 4-amino-4-oxobutanoil como inibidores de replicação viral BRPI0922912A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12137808P 2008-12-10 2008-12-10
US22631709P 2009-07-17 2009-07-17
PCT/US2009/067506 WO2010068760A2 (en) 2008-12-10 2009-12-10 New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication

Publications (2)

Publication Number Publication Date
BRPI0922912A2 true BRPI0922912A2 (pt) 2016-01-26
BRPI0922912A8 BRPI0922912A8 (pt) 2018-01-02

Family

ID=42243312

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922912A BRPI0922912A8 (pt) 2008-12-10 2009-12-10 peptídeos de 4-amino-4-oxobutanoil como inibidores de replicação viral

Country Status (19)

Country Link
US (2) US8614180B2 (pt)
EP (1) EP2364309B1 (pt)
JP (1) JP5723783B2 (pt)
KR (1) KR101762842B1 (pt)
CN (1) CN102245599B (pt)
AU (1) AU2009324643B2 (pt)
BR (1) BRPI0922912A8 (pt)
CA (1) CA2746264C (pt)
CY (1) CY1116254T1 (pt)
DK (1) DK2364309T3 (pt)
EA (1) EA022134B1 (pt)
ES (1) ES2527166T3 (pt)
IL (1) IL212786A (pt)
MX (1) MX2011006244A (pt)
NZ (1) NZ592668A (pt)
PL (1) PL2364309T3 (pt)
PT (1) PT2364309E (pt)
SI (1) SI2364309T1 (pt)
WO (1) WO2010068760A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ574605A (en) 2006-07-13 2011-11-25 Achillion Pharmaceuticals Inc 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8435984B2 (en) * 2007-02-26 2013-05-07 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of HCV replication
EA021794B1 (ru) * 2008-12-10 2015-09-30 Ачиллион Фармасьютикалз, Инк. Циклические аналоги 4-амино-4-оксобутаноил пептидов, ингибиторы репликации вирусов
CN102245599B (zh) 2008-12-10 2014-05-14 艾其林医药公司 作为病毒复制抑制剂的新的4-氨基-4-氧代丁酰基肽
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX349079B (es) 2011-05-27 2017-07-07 Achillion Pharmaceuticals Inc Alifanos, ciclofanos, heterafanos, heterofanos, hetero-heterafanos y metalocenos sustituidos utiles para tratar infecciones por el vhc.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
BR112014006314A2 (pt) 2011-10-21 2017-04-11 Abbvie Inc métodos para tratamento do vírus da hepatite c (hcv) compreendendo pelo menos dois agentes antivirais de atuação direta, ribavirina, sem interferon
BR112015007879A2 (pt) 2012-10-19 2017-07-04 Bristol Myers Squibb Co inibidores do vírus da hepatite c
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014074658A1 (en) * 2012-11-09 2014-05-15 Bristol-Myers Squibb Company Macrocyclic compounds for inhibition of inhibitors of apoptosis
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
AU2014236502A1 (en) 2013-03-14 2015-10-01 Achillion Pharmaceuticals, Inc. Processes for producing Sovaprevir
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
WO2014145600A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
MX2015013020A (es) 2013-03-15 2016-06-10 Achillion Pharmaceuticals Inc Polimorfos de sovaprevir y metodos de fabricacion de los mismos.
KR20160003700A (ko) 2013-04-12 2016-01-11 아칠리온 파르마세우티칼스 인코포레이티드 C형간염 바이러스의 치료를 위한 고활성 뉴클레오시드 유도체
CN103396351B (zh) * 2013-08-09 2015-10-21 山东大学 吡咯烷类Bcl-2蛋白小分子抑制剂化合物及其制备、药物组合物与制药用途
CN109689063B (zh) 2016-04-28 2026-02-27 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN120887906A (zh) 2016-05-10 2025-11-04 C4医药公司 用于靶蛋白降解的螺环降解决定子体
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE93526T1 (de) 1989-07-19 1993-09-15 Upjohn Co Peptide mit diaminoglycolen als uebergangszustandmimik.
JP2668003B2 (ja) 1992-06-12 1997-10-27 ファイザー インク． ヒトの心臓キマーゼを含むアンギオテンシンｉキマーゼに関する阻害剤
DK0727419T3 (da) 1992-12-29 2002-06-10 Abbott Lab Mellemprodukter til fremstilling af forbindelser, som inhiberer retroviral protease
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
ATE327246T1 (de) 2000-11-20 2006-06-15 Bristol Myers Squibb Co Hepatitis c tripeptid inhibitoren
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
EP1506172B1 (en) * 2002-05-20 2011-03-30 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US20060199773A1 (en) * 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2003099316A1 (en) 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
US6878722B2 (en) * 2002-05-20 2005-04-12 Bristol-Myers Squibb Company Substituted cycloalkyl P1′ hepatitis C virus inhibitors
EP1408031A1 (en) 2002-10-09 2004-04-14 3 D Gene Pharma Pyrolidine derivatives useful in treatment of hepatitis C virus infection
US7601709B2 (en) * 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
JP2007524576A (ja) 2003-02-07 2007-08-30 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状のｃ型肝炎セリンプロテアーゼ阻害剤
CA2516018C (en) * 2003-03-05 2011-08-23 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
ES2320771T3 (es) 2003-04-16 2009-05-28 Bristol-Myers Squibb Company Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c.
US7176208B2 (en) * 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
NZ544076A (en) * 2003-05-21 2009-04-30 Boehringer Ingelheim Int Hepatitis C inhibitor compounds
WO2004113365A2 (en) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
EP1646642A2 (en) 2003-07-18 2006-04-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
JP4704342B2 (ja) 2003-09-22 2011-06-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスに対し活性な大環状ペプチド
TW201245229A (en) 2003-10-14 2012-11-16 Hoffmann La Roche Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) * 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
WO2005070955A1 (en) 2004-01-21 2005-08-04 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
DE602005017582D1 (en) 2004-01-30 2009-12-24 Medivir Ab Hcv ns-3 serine protease inhibitoren
US20050209135A1 (en) 2004-03-15 2005-09-22 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
BRPI0509467A (pt) 2004-03-30 2007-09-11 Intermune Inc compostos macrocìclicos como inibidores de replicação viral
EP1767010B1 (en) 2004-06-15 2015-11-11 Tekelec Global, Inc. Method, system, and computer program products for content-based screening of MMS messages
US20080311077A1 (en) 2004-07-16 2008-12-18 Kleem Chaudhary Antiviral Compounds
UY29016A1 (es) * 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
CA2573346C (en) 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
CN101039947A (zh) * 2004-08-09 2007-09-19 布里斯托尔-迈尔斯斯奎布公司 Hcv复制抑制剂
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7375218B2 (en) 2004-09-17 2008-05-20 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic HCV protease inhibitors
US7659263B2 (en) * 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5667745B2 (ja) 2005-03-08 2015-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状化合物を製造する方法
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1891089B1 (en) * 2005-06-02 2014-11-05 Merck Sharp & Dohme Corp. HCV protease inhibitors in combination with food
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US7601686B2 (en) * 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
WO2007009227A1 (en) 2005-07-20 2007-01-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
EA019888B1 (ru) 2005-07-25 2014-07-30 Интермьюн, Инк. Промежуточное соединение для получения макроциклических ингибиторов репликации вируса гепатита с и способ его синтеза
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
EP1934243B1 (en) 2005-09-09 2011-05-25 Boehringer Ingelheim International GmbH Ring-closing metathesis process for the preparation of macrocyclic peptides
ATE493409T1 (de) 2005-10-11 2011-01-15 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
US7772183B2 (en) * 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) * 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ574605A (en) * 2006-07-13 2011-11-25 Achillion Pharmaceuticals Inc 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
EP1881002A1 (en) 2006-07-20 2008-01-23 Tibotec Pharmaceuticals Ltd. HCV NS-3 serine protease inhibitors
CN101668538A (zh) 2007-01-08 2010-03-10 芬诺密克斯公司 大环类丙型肝炎蛋白酶抑制剂
US20080207528A1 (en) 2007-02-01 2008-08-28 Syaulan Yang Hcv protease inhibitors
CN102245599B (zh) * 2008-12-10 2014-05-14 艾其林医药公司 作为病毒复制抑制剂的新的4-氨基-4-氧代丁酰基肽

Also Published As

Publication number Publication date
EA201100928A1 (ru) 2011-12-30
HK1156623A1 (en) 2012-06-15
PT2364309E (pt) 2015-01-14
WO2010068760A2 (en) 2010-06-17
PL2364309T3 (pl) 2015-03-31
MX2011006244A (es) 2011-06-27
JP2012511587A (ja) 2012-05-24
BRPI0922912A8 (pt) 2018-01-02
NZ592668A (en) 2013-12-20
ES2527166T3 (es) 2015-01-21
CA2746264C (en) 2017-11-14
US20100216725A1 (en) 2010-08-26
US20140113890A1 (en) 2014-04-24
DK2364309T3 (en) 2015-01-12
SI2364309T1 (sl) 2015-03-31
AU2009324643A1 (en) 2010-06-17
EP2364309A2 (en) 2011-09-14
KR20110114566A (ko) 2011-10-19
EP2364309B1 (en) 2014-10-01
JP5723783B2 (ja) 2015-05-27
US8614180B2 (en) 2013-12-24
WO2010068760A3 (en) 2010-10-14
EA022134B1 (ru) 2015-11-30
AU2009324643B2 (en) 2014-08-28
IL212786A0 (en) 2011-07-31
IL212786A (en) 2014-11-30
KR101762842B1 (ko) 2017-08-04
CN102245599B (zh) 2014-05-14
CA2746264A1 (en) 2010-06-17
CY1116254T1 (el) 2017-02-08
US9133115B2 (en) 2015-09-15
CN102245599A (zh) 2011-11-16
EP2364309A4 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
BRPI0922912A8 (pt) peptídeos de 4-amino-4-oxobutanoil como inibidores de replicação viral
LTPA2016048I1 (lt) Hepatito C viruso replikacijos inhibitoriai
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
EP2406399A4 (en) MIRAC PROTEINS
HUE041436T2 (hu) Tal-effektor-közvetített DNS-módosítás
DE112009004699A5 (de) Elektrochirurgisches System
BRPI0920135A2 (pt) imidazopiridazinacarbonitrilos úteis como inibidores de quinase
EP2320221A4 (en) ELECTRODE
BRPI1007836A2 (pt) Inibidores do vírus c da hepatite
BRPI1008846A2 (pt) inibidores do vírus da hepatite c
BRPI1013393A2 (pt) inibidores do vírus da hepatite c
BRPI1014084A2 (pt) inibidores do vírus da hepatite c
EP2244670A4 (en) INTERSPINED DISTANCE MEMBER
ME03605B (me) Inhibitori virusne replikacije
BRPI0922913A2 (pt) Análogos cíclicos de peptídeo 4-amino-4-oxobutanoil inibidores de replicação viral
HRP20180429T1 (hr) Raspršivač
EP2472185A4 (en) HEATING DEVICE
BR112012005382A2 (pt) inibidores de jak
DK2310613T3 (da) Forbedret brudled til stigrør
BRPI1010661A2 (pt) peptídeo
BR112012006603A2 (pt) braçadeira de fixação
ITPD20090053U1 (it) Paradordi per banchine
FI20095455L (fi) Kirves
FR2949371B3 (fr) Agrafeuse
IT1397994B1 (it) Morsetto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2385 DE 20/09/2016.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements